Patents by Inventor Michael B. Widmer

Michael B. Widmer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6613320
    Abstract: CD4+ cells obtained from individuals with defective CD40L gene and transfected with a vector containing CD40-L are described.
    Type: Grant
    Filed: April 10, 2000
    Date of Patent: September 2, 2003
    Assignee: Immunex Corporation
    Inventors: Melanie K. Spriggs, Richard J. Armitage, William C. Fanslow, III, Michael B. Widmer, Barry L. Davison, Blair R. Renshaw
  • Patent number: 6106832
    Abstract: There is disclosed a method of detecting a mutation in a CD40 ligand gene, comprising isolating nucleic acid from an individual, selectively amplifying nucleic acid derived from the CD40 ligand gene, and analyzing the amplified nucleic acid to determine if there is a mutation (or mutations) in the CD40 ligand gene. The ability of a CD40 ligand protein expressed from the gene may be determined. Methods of treating individuals exhibiting a defective CD40 ligand gene (i.e., X-linked hyper IgM patients and certain individuals afflicted with combined variable immunodeficiency) are also disclosed. Also disclosed are non-human animals that lack functional CD40 ligand as a result of gene targeting technology.
    Type: Grant
    Filed: January 22, 1996
    Date of Patent: August 22, 2000
    Assignee: Immunex Corporation
    Inventors: Melanie K. Spriggs, Richard J. Armitage, William C. Fanslow, III, Michael B. Widmer
  • Patent number: 5747024
    Abstract: Methods of enhancing a mammal's immune response to a vaccine antigen are disclosed. Interleukin-15 can be used as a vaccine adjuvant to enhance or potentiate the immune response to a vaccine. Compositions comprising an immunogenic amount of vaccine antigen and an immunogenicity-augmenting amount of IL-15 are also provided by the invention. IL-15 can be used alone in the invention or in concurrent or sequential combination with additional vaccine adjuvants.
    Type: Grant
    Filed: July 19, 1995
    Date of Patent: May 5, 1998
    Assignee: Immunex Corporation
    Inventors: Kenneth H. Grabstein, Michael B. Widmer